StockData
Acrivon Therapeutics, Inc. logo

Acrivon Therapeutics, Inc. (ACRV) stock

ACRVNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$1.56+0.13 (+9.09%)

Close on Nov 18, 2026Market cap $66.85MP/E –Yield –

Acrivon Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Acrivon Therapeutics's price to book ratio was 0.8× on Nov 11, 2026, against 0.6× a year earlier. Over the last 4 years it ranged from 0.2× to 2.6×, with a median of 0.9×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20260.8×+0.2
2025Dec 31, 20250.6×−0.4
2024Dec 31, 20241.0×+0.2
2023Dec 29, 20230.8×–

More Acrivon Therapeutics figures

See a number that looks wrong?